Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

102.36
+0.20000.20%
Volume:8K
Turnover:814.73K
Market Cap:4.21B
PE:-99.54
High:102.36
Open:102.36
Low:102.36
Close:102.16
52wk High:107.69
52wk Low:85.36
Shares:41.10M
Float Shares:41.10M
Volume Ratio:2.82
T/O Rate:0.02%
Dividend:1.44
Dividend Rate:1.41%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.09
PE(LYR):-99.54

Loading ...

Scotiabank Remains a Buy on AbbVie (ABBV)

TIPRANKS
·
Sep 04

UnitedHealth (UNH) Gets a Buy from Bernstein

TIPRANKS
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
Sep 04

CurveBeam AI Details Director Appointment and Equity Interests

TIPRANKS
·
Sep 04

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 04

DBV Technologies Steps Up Investor Outreach Ahead of Key Food Allergy Trial Milestones

TIPRANKS
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Sep 03

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Sep 03

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Sep 03

Press Release: PatientIQ Raises $30 Million Series C to Power the Next Generation of Patient-Reported Outcomes Intelligence

Dow Jones
·
Sep 03

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Sep 03

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Sep 03

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Sep 03

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 03